
News|Podcasts|January 17, 2024
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment
Author(s)ZS Associates
Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content





The Transformative Role of Medical Information in Customer Engagement
ByIndegene
Published: | Updated:
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Approves Hernexeos
2
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
3
FDA Approves Hernexeos Under National Priority Voucher Program
4
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
5
